This week, we talk all about disseminated testicular cancer, highlighting our current treatment modalities and why we do what we do. We also cover refractory disease. This episode builds on our prior discussions in Parts 1 and 2, so be sure to check these out if you haven’t already!

Episode contents:

- A history lesson about how we developed our current risk stratification model

- Our current treatment paradigms and regimens for disseminated seminoma and non-seminoma

- To resect or not to resect?

- How we approach relapsed/refractory disease

****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email

** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

Episode 129: Testicular Cancer Series, Pt 3 - Disseminated and relapsed/refractory disease

The Fellow on Call: The Heme/Onc Podcast